H.C. Wainwright initiated coverage on MetaVia with a new price target
$MTVA
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/30/2024 | $12.00 | Buy | H.C. Wainwright |
CAMBRIDGE, Mass., Aug. 26, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences. September 3-5: Wells Fargo Healthcare Conference. Hyung Heon Kim, President and Chief Executive Officer will attend this conference in Boston, Massachusetts.September 8-10: H.C. Wainwright 27th Annual Global Investment Conference. Mr. Kim will participate in fireside chat. The Company's on-demand presentation will be available to view
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected in the Fourth Quarter of 2025 Signed AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 Beyond MASH $17.6 Million in Cash at End of Second Quarter is Expected to Fund the Company Into 2026 CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate strategic update.
Extension is Designed to Assess Early Efficacy and Patient Safety and Tolerability with Longer-Term Exposure to DA-1726 and Further Explore Non-Titrated Maximum Tolerated Dose Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has extended to 8 weeks from 4 weeks, the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, and has administered a fifth weekly dose to the first patient. DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-lik
SCHEDULE 13G/A - MetaVia Inc. (0001638287) (Subject)
8-K - MetaVia Inc. (0001638287) (Filer)
10-Q - MetaVia Inc. (0001638287) (Filer)
H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)